Clever Culture Systems (ASX: CC5) is advancing the commercial rollout of its APAS Independence platform, with CEO Brent Barnes highlighting a growing global pharmaceutical customer base and increasing opportunities to scale deployments across existing customers.
Brent discusses the company’s progress in expanding its pharmaceutical customer base from four to eight, including major global manufacturers, and explains how its Land and Expand strategy is designed to turn initial instrument placements into broader deployments. AstraZeneca provides an example of the strategy, progressing from an initial APAS Independence instrument to 12 instruments installed globally.
This interview also explores the recurring revenue generated from software and service agreements attached to APAS installations, customer advocacy and the company’s growing commercial pipeline. Looking ahead, Brent outlines expectations for a step-change in sales growth in FY27, supported by further expansion within existing pharmaceutical customers and new opportunities across the sector.
Watch the full interview to hear more about Clever Culture Systems’ commercial strategy, global pharmaceutical expansion and outlook for FY27.
